US Pharma MarketingBioCryst ends internal discovery programs, will close Alabama research facility
BioCryst is shutting down internal drug discovery and closing its Birmingham, AL research site, cutting 2026 opex guidance to $420–$440M while continuing work on navenibart and BCX17725. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR…
BioCryst Pharmaceuticals is winding down its own drug discovery work, saying that it plans to look for future drug programs externally.
The company announced a plan to discontinue its internal discovery ...
Source: Endpoints News